Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Among authors: berardi r. Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Breast Cancer Res Treat. 2017. PMID: 28289852
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: berardi r. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: berardi r. J Clin Oncol. 2007 Sep 1;25(25):3930-5. doi: 10.1200/JCO.2007.11.5022. J Clin Oncol. 2007. PMID: 17761976
Pancreatic cancer: progress in cancer therapy.
Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pierantoni C, et al. Among authors: berardi r. Crit Rev Oncol Hematol. 2008 Jul;67(1):27-38. doi: 10.1016/j.critrevonc.2008.01.009. Epub 2008 Mar 19. Crit Rev Oncol Hematol. 2008. PMID: 18356073 Review.
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: berardi r. BMC Cancer. 2009 Aug 27;9:303. doi: 10.1186/1471-2407-9-303. BMC Cancer. 2009. PMID: 19712476 Free PMC article.
641 results